



FOR IMMEDIATE RELEASE

September 21<sup>st</sup>, 2022

**Anwita Biosciences Announced Today Dosing of First Patient in Its Phase I Clinical Trial of JS014, a Half-life Extended IL-21, for the Treatment of Solid Tumors**

SAN CARLOS, California, September 21<sup>st</sup>, 2022 – Anwita Biosciences, Inc. (“Anwita”), a clinical-stage innovative biopharmaceutical company developing proprietary optimized cytokine-based therapeutics for cancer patients, today announced the dosing of the first patient in a Phase Ia/Ib clinical trial of JS014, an Exenokine-21 molecule designed to extend the half-life of Interleukine-21 (IL-21), for the treatment of patients with solid tumors.

“We are proud of reaching this important milestone for dosing the first patient in our Phase 1 trial of JS014” said Ziyang Zhong, Chief Executive Officer of Anwita. “JS014 is the first product from our diverse portfolio of cytokines to enter the clinic. We are excited to follow the progress of JS014 in the Phase I trial. With a prolonged systemic exposure as a consequence of its extended half-life, we expect JS014 would improve patient compliance and potentially provide a better antitumor response than the unmodified recombinant IL-21.”

The Phase I open label trial will evaluate the safety and potential response, as well as pharmacokinetics, pharmacodynamics, and immunogenicity of JS014 as a single agent and as a combined agent with a flat dose of pembrolizumab in approximately 60 patients with advanced cancers who have failed standard therapy. The results from Phase I study will provide recommended Phase II dose to further explore the antitumor activities of JS014 in future clinical studies. JS014 is currently in a strategic partnership with Shanghai Junshi Biosciences who is conducting a Phase I study in Greater China. Worldwide rights (excluding Greater China) for JS014 are available.

**About Anwita Biosciences, Inc.**

Anwita Biosciences, Inc. is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. Anwita specializes in the discovery and development of optimized immunotherapeutics, leveraging its core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering.

**Investor Relations**

Contact: Investor Relations

Telephone: (650) 600-9828

Email: [contact@anwitabio.com](mailto:contact@anwitabio.com)

Website: [www.anwitabio.com](http://www.anwitabio.com)